trending Market Intelligence /marketintelligence/en/news-insights/trending/e0bqe_8vxriodrsns-4tkq2 content esgSubNav
In This List

CTI BioPharma Corp.'s restructuring plan includes 50% employee reduction

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


CTI BioPharma Corp.'s restructuring plan includes 50% employee reduction

CTI BioPharma Corp. will begin a restructuring plan that includes a workforce reduction of 50% across the total number of the company's employees.

The employee reductions will lead to cost savings of an estimated $20 million over three years, according to the company's Dec. 13 press release.

The Seattle-based biopharmaceutical company said the restructuring will improve efficiencies and preserve capital for pacritinib, the company's investigational treatment for myelofibrosis.

Myelofibrosis is a bone marrow disorder that disrupts the body's ability to reproduce red blood cells, according to the Mayo Clinic.

CTI BioPharma will provide financial guidance for the treatment in the first half of 2019 when it determines the details of the U.S. Phase 3 trial design, according to the press release.